TIME: Circadian Timing, Information Processing and Energy Balance Study

Sponsor
University of Utah (Other)
Overall Status
Recruiting
CT.gov ID
NCT04759755
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH), Rush University Medical Center (Other), University of Illinois at Chicago (Other)
120
1
48
2.5

Study Details

Study Description

Brief Summary

This study design will test biological and behavioral mechanisms in the cross-sectional analyses and determine the prospective effects of circadian alignment and sleep on changes in cardiometabolic risk factors.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The goal of this study is to determine how sleep and circadian rhythm alignment contribute to neurobehavioral and behavioral mechanisms of cardiometabolic risk. The investigators propose that circadian misalignment, which is more common among individuals with late sleep timing, leads to increased consumption of energy dense/prepared foods and to decreased insulin sensitivity. Short sleep duration and neurobehavioral measures (i.e. delay discounting) may moderate these associations, thus exacerbating cardiometabolic risk factors. There is evidence for a direct biological link between circadian misalignment and insulin resistance, and for a relationship that is mediated through changes in eating behaviors. Insulin resistance and increased caloric intake over time lead to increased BMI and body fat.

    In this study, the investigators will conduct cross-sectional and longitudinal analyses to determine biological and behavioral mechanisms that link circadian alignment and sleep duration to changes in cardiometabolic risk over 1 year. This study will identify individual differences that predict risk for cardiometabolic disorders and suggest potential for sleep, circadian and neurobehavioral interventions to reduce cardiometabolic risk.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Ecologic or Community
    Time Perspective:
    Prospective
    Official Title:
    Circadian and Sleep Pathways to Cardiometabolic Disease Risk: Role of Neurobehavioral Processes
    Actual Study Start Date :
    May 29, 2019
    Anticipated Primary Completion Date :
    May 29, 2023
    Anticipated Study Completion Date :
    May 29, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    Study participants

    18-60 year olds who demonstrate habitual sleep onset time between 10:00 pm-3:00 am and BMI 25-39.9.

    Outcome Measures

    Primary Outcome Measures

    1. Insulin resistance [Baseline]

      Measured by a frequently sampled IV glucose tolerance test

    Secondary Outcome Measures

    1. Eating behaviors [12 months]

      Healthy Eating Index will be calculated from the Automated Self-Assessment of 24 hour diet recall (ASA-24)

    2. Delay discounting [Baseline]

      Measured by a 10 item adjusting delay discounting measure

    Other Outcome Measures

    1. Body mass index [12 months]

      Height and weight will be measured at screening and 1 year follow-up

    2. Metabolic control [12 months]

      HbA1c will be measured at screening and 12-month follow-up

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Demonstrate habitual sleep onset time between 10:00 pm-3:00 am on actigraphy;

    • able to read and write in English;

    • BMI 25-39.9 (overweight, class one obesity, or class two obesity)

    Exclusion Criteria:
    • High risk or presence of sleep disorders (obstructive sleep apnea (OSA), restless legs syndrome, or insomnia) as assessed by the questionnaires and overnight OSA screening;

    • Diagnosed with diabetes or HbA1c>7 at screening or taking medications known to affect glucose;

    • History of cognitive or neurological disorders;

    • Presence of major psychiatric disorders, current alcohol or substance abuse as determined by screening questionnaires or self-report;

    • Unstable or serious medical illness;

    • Overnight shift work or travel over 2 time zones in the past 2 months;

    • Use of hypnotic, stimulant or medications know to affect melatonin concentrations such as beta blockers, daily NSAIDs;

    • Current smoking;

    • Daily caffeine intake >300 mg;

    • Pregnant or lactating;

    • Currently on a restrictive of special diet.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Utah Salt Lake City Utah United States 84108

    Sponsors and Collaborators

    • University of Utah
    • National Heart, Lung, and Blood Institute (NHLBI)
    • Rush University Medical Center
    • University of Illinois at Chicago

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kelly Glazer Baron, Associate Professor, University of Utah
    ClinicalTrials.gov Identifier:
    NCT04759755
    Other Study ID Numbers:
    • 00117438
    • 1R01HL141706-01A1
    First Posted:
    Feb 18, 2021
    Last Update Posted:
    Nov 17, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 17, 2021